Moleculin Biotech, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Moleculin announced acceptance of Annamycin (naxtarubicin) interim data from the pivotal MB-108 Phase 2/3 MIRACLE trial for presentation at ASH Annual Meeting (December 12–15, 2026). Among 45 randomized patients, complete remission rates were 43% and 36% in two Annamycin arms versus 12% in placebo; no cardiotoxicity observed. The independent Data Monitoring Committee recommended continuation of the study without amendment across all three arms.
Why this rating
Positive interim efficacy data (43%/36% vs 12% remission) on lead drug supports path to NDA. For an $8.8M-market-cap biotech, successful Phase 3 milestone materially de-risks pipeline; however, interim data not final approval. Real but not certain.
Price action (we called it positive)
before filing · preread $8.43 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.